VIETNAM · MEDICAL DEVICES
Vietnam’s six medical device procurement groups from 2027: which can an NMPA approval support?
Vietnam’s Ministry of Health Circular 57/2025/TT-BYT took effect on 15 February 2026. It sorts medical devices into six procurement groups by technical standard and quality, and the grouping applies from 1 January 2027. The appendix reference list includes China’s “central-level” NMPA, giving Chinese manufacturers a usable source for the quality criterion. Whether a product actually qualifies for a target group still depends on the form of technical evidence, and on the standards and reference market the user unit selects for that procurement. (Source: Circular 57/2025 full text, Articles 4–6 and Appendix)
For manufacturers targeting Vietnamese hospital procurement, preparation has to be done model by model: is the device lawfully marketed in Vietnam, which standards apply, which documents prove conformity, and in which reference market is it authorised. A Chinese registration certificate alone, or a Vietnamese marketing number alone, is not enough to settle the procurement group.
Procurement groups versus registration Classes A to D: what does each do?
Circular 57 implements Article 146(2)(d) of Decree 214/2025/ND-CP (detailing the Law on Bidding) and guides how medical devices are grouped by technical standard and quality for procurement. Classes A, B, C and D are risk classes used for registration and other regulatory requirements; Circular 57 does not mention risk classification at all. Record the two in separate columns of your product list: Class C does not translate into procurement Group 3. (Source: Circular 57/2025, Article 1)
Article 3 requires a device being grouped to meet, at the same time, the technical standard and quality criteria matching the user unit’s professional requirements and needs, and to be lawfully marketed in Vietnam. Under Article 8, the head of the unit carrying out the grouping decides it in line with management and use requirements and the user unit’s needs, and must ensure competition within each group, fairness and transparency; the Vietnamese marketing number holder is responsible for the supporting documents. Manufacturers can prepare the evidence, but cannot label a product with a fixed group that applies to every procurement. (Source: Circular 57/2025, Articles 3 and 8)
How do the six groups compare?
Start with the technical evidence. Article 2(1) lists the permitted types of standard: national, international, regional, foreign and company (tiêu chuẩn cơ sở) standards; the specific standard is selected by the user unit under each group’s criteria. Article 2(2) sets out three forms of proof:
- Point a: a certificate of conformity to standard (chứng nhận hợp chuẩn) obtained under Vietnamese law on standards and technical regulations.
- Point b: a conformity assessment result from either an international conformity assessment body, or a domestic or foreign conformity assessment body lawfully established and operating in Vietnam.
- Point c: documents from the device owner showing that the device meets the technical standards required by the user unit.
Points a, b and c are paragraph letters and have nothing to do with risk Classes A, B or C. The Circular does not further define an “international conformity assessment body”, so whether a given overseas laboratory report will be accepted under point b should be confirmed against the user unit’s requirements.
Article 2(3) bases quality on the device already being authorised for marketing in one or more countries or territories. The table summarises the six groups in Article 4; in every group, both the specific standards and the reference market are “selected by the user unit”.
| Group | Accepted technical evidence (Article 2(2)) | Quality: authorised by at least one body, country or territory |
|---|---|---|
| Group 1 | Point a | Selected by the user unit from the appendix list |
| Group 2 | Point a | Selected by the user unit from outside the appendix list |
| Group 3 | Point a or b | Selected by the user unit from the appendix list |
| Group 4 | Point a or b | Selected by the user unit from outside the appendix list |
| Group 5 | Point a, b or c | Selected by the user unit from the appendix list |
| Group 6 | Point a, b or c | Selected by the user unit from outside the appendix list |
Groups 1/2, 3/4 and 5/6 share the same level of technical evidence; the only difference within each pair is whether the quality reference is on the appendix list. Groups 3 and 5 also accept point a evidence, so they should not be described as accepting only b or c. Devices manufactured in Vietnam are dealt with under Article 3(2): if they meet the technical standard selected by the user unit and are lawfully marketed in Vietnam, they may take part in all the corresponding groups in Article 4, without the foreign-approval condition that applies to imports. (Source: Circular 57/2025, Articles 2–4)
NMPA is on the list: how should Chinese manufacturers use it?
The appendix lists nine reference sources: the US FDA, Australia’s TGA, Health Canada, Japan’s MHLW or PMDA, EU member states, the United Kingdom, Switzerland, China’s central-level NMPA, and Korea’s MFDS or NIDS. The Chinese entry reads “Cục Quản lý sản phẩm y tế quốc gia cấp trung ương (NMPA)”, expressly specifying “central level”. (Source: Circular 57/2025, Appendix)
This matters in practice. Under China’s Regulations on the Supervision and Administration of Medical Devices, domestic Class II devices are registered with the provincial drug regulatory department where the applicant is located, while domestic Class III devices and imported Class II and III devices are registered with the State Council drug regulator (NMPA); domestic Class I devices are filed with the municipal-level department. (Source: State Council Decree No. 739, Articles 15 and 16) The Circular does not say whether a domestic Class II certificate issued by a provincial authority, or a municipal Class I filing, satisfies the “central-level NMPA” entry, so do not assume it does. Check the issuing authority, product scope and validity on each certificate, and confirm the position for the specific tender with the number holder and the user unit.
Even where the approving body is on the list, what counts is the reference market the user unit chooses for that tender. If it selects another listed market, a Chinese approval will not automatically satisfy the quality criterion. Separately, the technical documents must cover the models being tendered, the standards the user unit has selected and the required form of evidence. Check the two sides independently.
Illustrative example: an imported device lawfully marketed in Vietnam holds an NMPA-issued registration certificate and technical documents from the device owner. Only if the tender selects China as the quality reference market and accepts point c evidence is there a basis to assess it for Group 5. To be assessed for Group 1, it would still need a point a certificate of conformity. The example illustrates how evidence combines; it does not determine eligibility for any product or tender.
Before 2027: build an evidence pack you can use model by model
Start with the main models you intend to offer in hospital procurement, and have the manufacturer, the Vietnamese marketing number holder and the bidder check them together against the target tender’s conditions. The table is MediPass’s suggested division of work, not an official submission form.
| Item | Suggested lead | Output |
|---|---|---|
| Basis for lawful marketing in Vietnam | Marketing number holder | Number, holder, product and model scope matched to the products to be sold. |
| Foreign marketing authorisations | Manufacturer / device owner | Issuing authority, country, validity and models matched, and aligned with the reference market selected for the tender. |
| Technical standards and evidence | Manufacturer / technical team | Each standard and version listed, with the point a/b/c form of evidence and supporting documents. |
| Tender conditions | Bidder and number holder | The user unit’s selected markets, standards and group requirements mapped item by item to the evidence. |
| Version control | All three parties | Consistent models, product names, document versions and translations, with gaps and owners recorded. |
As the marketing number holder is legally responsible for the supporting documents, it should be able to obtain and explain the key records, rather than leaving the sales team with screenshots of certificates. When the registration scope or product documents change, update the procurement evidence pack too. For basic market access, see Vietnam medical device registration; for licence-holding and document handover, see local representation and licence holding.
Frequently asked questions
If we have CE marking, are we automatically in Group 1?
No. EU member states are on the appendix list and can support the quality criterion, but Group 1 accepts only point a technical evidence, a certificate of conformity obtained under Vietnamese law; CE documents do not automatically substitute for it. The reference market selected by the user unit, the models and the intended use also need checking.
Can one product meet the conditions of several groups?
Some groups in Article 4 accept more than one form of technical evidence, so the same evidence may meet several groups’ conditions. The actual group is decided by the unit carrying out the grouping according to the needs of that procurement; do not promote a product as holding a permanent “top group” for every tender.
Can a Chinese certificate issued by a provincial regulator be used?
The appendix refers to the “central-level NMPA”, and the Circular does not say whether provincial certificates are equivalent. Check the issuing authority first; for a provincially issued certificate, confirm the position for the specific tender with the number holder and the user unit rather than presenting it as a listed source.
We already hold a Vietnamese marketing number. Do we need to re-register?
Circular 57 sets out procurement grouping and evidence requirements; it does not itself create a re-registration obligation. Check that your existing marketing scope and documents are accurate, then fill the procurement evidence gaps. If the product has separate changes that must be notified, handle them under the applicable registration rules.
Official references
- Vietnam Ministry of Health, Circular 57/2025/TT-BYT guiding the grouping of medical devices by technical standard and quality, Article 1: basis in Decree 214/2025, Article 146(2)(d); Articles 2–4: evidence forms and six groups; Article 5: in force 15 February 2026; Article 6: grouping from 1 January 2027; Article 8: responsibilities; Appendix: reference list, issued 31 December 2025, datafiles.chinhphu.vn (PDF)
- State Council Decree No. 739, Regulations on the Supervision and Administration of Medical Devices (China), Article 15: Class I filing; Article 16: Class II and III registration, promulgated 9 February 2021, in force 1 June 2021, gov.cn
- Government of Viet Nam legal documents portal, registry page for Circular 57/2025/TT-BYT (number, issued 31 December 2025, effective 15 February 2026, signed by Đỗ Xuân Tuyên), vanban.chinhphu.vn
Prepared from official sources verifiable as of 17 February 2026 for manufacturers’ project planning; the procurement group for a specific product must be confirmed against the user unit’s choices and the tender documents.
